Clinical trial
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat…
NCT00260364 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00260364 |
|---|---|
| Title | Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer |
| Official title | A Phase I-II Dose Finding and Early Efficacy Study of Combination Therapy With Erlotinib (Tarceva), Gemcitabine, Bevacizumab (Avastin), and Capecitabine in Advanced Pancreatic Cancer |
| Acronym | TARGET |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Collaborators | Professor Cunningham's Clinical Research Fund Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle, Capecitabine orally days 1 -21, Erlotinib 100 mg orally days 1-28, Bevacizumab 5 mg/kg intravenously every 2 weeks |
| Enrollment | 44 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Dec 1, 2005 |
| Last update posted | Oct 14, 2016 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: